Supportive therapies for myeloid leukemia including blood transfusion and growth factors

Hisayuki Yao, Eishi Ashihara, Taira Maekawa

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Bone marrow suppression after intensive chemotherapies in patients with myeloid leukemia is severe, resulting in the reduction of the number of white blood cells, red blood cells, and platelets. Supportive therapies are indispensable for the management of these leukemia patients. The improvement of blood cell transfusion can decrease side effects of chemotherapies and establish the safety. But we still have notable side effects of transfusion such as TRALI (transfusion-related acute lung injury), platelet immunologic refractory state, and so on. Cytokine therapy especially with G-CSF (granulocyte colony-stimulating factor) administration, changed the treatment of myeloid leukemia. G-CSF can shorten the duration of neutropenia and decrease the risk of infection. Recently the effects of Epo (erythropoietin) on chemotherapy-induced anemia have been demonstrated. We discuss here the indications of blood cell transfusion and cytokine therapies in the treatment for myeloid leukemia.

Original languageEnglish
Pages (from-to)1951-1957
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number10
Publication statusPublished - Oct 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Supportive therapies for myeloid leukemia including blood transfusion and growth factors'. Together they form a unique fingerprint.

Cite this